P66 Adalimumab originator versus biosimilar in children and young people with JIA

INTRODUCTION/BACKGROUND: Biosimilar therapies are considered to have comparable efficacy to their originators and prescribing is encouraged in the UK for significant cost-savings to the NHS. However, real-world evidence comparing originators and biosimilars is limited, particularly in children and y...

Descripción completa

Detalles Bibliográficos
Autores principales: Kearsley-Fleet, Lianne, Jain, Sarthak, Baildam, Eileen, Beresford, Michael W, Douglas, Sharon, Foster, Helen E, Southwood, Taunton R, Hyrich, Kimme L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515880/
http://dx.doi.org/10.1093/rap/rkac067.066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515880/
http://dx.doi.org/10.1093/rap/rkac067.066

Ejemplares similares